Main menu


You are here

Africa

ANALYSIS of the difficulties in comparing vaccines

Yusuff Adebayo Adebisi knows that a vaccine that offers 70% protection against COVID-19 could be a valuable tool against the coronavirus pandemic in Nigeria — especially if that vaccine is cheap and doesn’t have to be stored at extremely cold temperatures. But what if another vaccine — one that is more expensive to buy and to store — was 95% effective?

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

NIH to launch research into Covid long term effects, plus international roundup

Roundup:  NIH to study ‘long-haul’ virus symptoms

  WASHINGTON  (AP) — The National Institutes of Health is launching research to understand the causes and consequences of the lingering brain fog, breathing problems and malaise reported by many recovering COVID-19 patients.

Dr. Anthony Fauci says some studies have shown up to 30% of patients report symptoms that can endure for months, complicating their return to normal routines and work, and plunging many recovering patients into depression.

Fauci noted at a White House coronavirus briefing on Wednesday that work at NIH started this week thanks to more than $1 billion provided by Congress for COVID-related medical research. Government scientists are looking to enlist doctors and research institutions around the country in the effort to learn about “long-haul” COVID-19.

Problem, Solution, SitRep, or ?: 

WHO listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use

WHO listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use, giving the green light for these vaccines to be rolled out globally through COVAX. The vaccines are produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India.

Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Africa
howdy folks
Page loaded in 0.777 seconds.